

IN THE CLAIMS

Please amend claims 2-7, and add claims 32-34 as follows:

1. (withdrawn)

2. (currently amended) An isolated nucleic acid molecule comprising a nucleotide sequences selected from the group consisting of:

a) ~~the~~ a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 446) or Figure 3A (SEQ ID NO: 611) ~~or Figure 12A (SEQ ID NO: 16)~~;

b) ~~the~~ a nucleotide sequence encoding ~~the~~ a polypeptide as set forth in Figure 2A (SEQ ID NO. 67) from residues 1-322 or from residues 47-322, or as set forth in Figure 3A (SEQ ID NO: 4412) from residues 1-288 or from residues 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288 ~~or as set forth in Figure 12A from residues 1-302, or from residues 19-302, 20-302, 21-302, 22-302, 24-302 or 28-302, wherein the~~ polypeptide has at least one activity characteristic of B7RP1;

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 67) or Figure 3A (SEQ ID NO: 4412) ~~or Figure 12A (SEQ ID NO: 6)~~; wherein the polypeptide has at least one activity characteristic of B7RP1;

d) ~~a naturally occurring allelic variant or alternate splice variant of any of (a), (b), or (c)~~;

ed) a nucleotide sequence complementary to any of (a), (b), or (c);

fe) a nucleotide sequence of (b) ~~or (c)~~ ~~or (d)~~ encoding a polypeptide fragment of at least about 25, 50, 75, 100, ~~or greater than 100~~ amino acid residues, wherein the polypeptide has at least one activity characteristic of B7RP1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

gf) a nucleotide sequence of (a), (b), or (c) comprising a fragment of at least about 10, 15, 20, 25, 50, 75, 100, or greater than 100 nucleotides; and

hg) a nucleotide sequence which hybridizes over its entire length under ~~stringent~~ high stringency conditions to the complement of any of (a)-(gf).

3. (currently amended) ~~The A nucleic acid molecule of Claims 1 or 2 wherein the nucleotide sequence which~~ is operably linked to an expression control sequence, wherein the nucleic acid molecule is selected from:

a) a nucleotide sequence as set forth in Figure 1A (SEQ ID NO: 1);

b) a nucleotide sequence encoding a polypeptide as set forth in Figure 1A (SEQ ID NO: 2) from residues 1-200 or from residues 21-200, wherein the polypeptide has at least one activity characteristic of CRP1;

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 1A (SEQ ID NO: 2), wherein the polypeptide has at least one activity characteristic of CRP1;

d) a nucleotide sequence complementary to any of (a), (b), or (c);

e) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide has at least one activity characteristic of CRP1;

f) a nucleotide sequence that hybridizes over its entire length under high stringency conditions to the complement of any of (a)-(e), wherein the nucleotide encodes a polypeptide that has at least one activity characteristic of CRP1; and

g) the nucleotide of claim 2.

4. (currently amended) A host cell comprising the nucleic acid molecule of Claim 23.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

5. (currently amended) The host cell of Claim 3-4 which is a eucaryotic cell.
6. (currently amended) The host cell of Claim 3-4 which is a procaryotic cell.
7. (currently amended) A process for producing a polypeptide comprising growing a culture of the host cell of Claim 3-4 in suitable culture medium and isolating the polypeptide from the culture.

8-31. (withdrawn)

32. (new) The isolated nucleic acid molecule of claim 2 comprising a nucleic acid sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11).

E 10
33. (new) The isolated nucleic acid molecule of claim 2 comprising a nucleotide sequence encoding a polypeptide as set forth in Figure 2A (SEQ ID NO: 7) from residues 1-322 or 47-322, or as set forth in Figure 3A (SEQ ID NO: 12) from residues 1-288, 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288, wherein the polypeptide has at least one activity characteristic of B7RP1.

34. (new) An isolated nucleic acid molecule encoding a polypeptide comprising a fragment of at least about 50 amino acid residues, wherein the fragment comprises an amino acid sequence that is at least about 70% identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12), and wherein the fragment has at least one activity characteristic of B7RP1.

35. (new) An isolated nucleic acid molecule comprising a nucleic acid sequence as set forth in Figure 12A (SEQ ID NO: 16).

36. (new) An isolated nucleic acid molecule encoding a polypeptide as set forth in Figure 12A (SEQ ID NO: 17) comprising an amino terminus at about residue 1, 19, 20, 21, 22, 24, or 28; wherein the polypeptide has at least one activity characteristic of B7RP1.

E
10

37. (new) An isolated nucleic acid molecule encoding a polypeptide as set forth in Figure 12A (SEQ ID NO: 17) comprising a carboxy terminus at about residue 302, wherein the polypeptide has at least one activity characteristic of B7RP1.

38. (new) An isolated nucleic acid molecule consisting of a nucleic acid sequence as set forth in Figure 12A (SEQ ID NO: 16).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com